hot stocks to buy

I've said it for years… The biggest gains will come in the final innings of the bull market.   My friend, the final innings have arrived. The big moment is here.   Yesterday, I explained my "Melt Up" thesis, and why I believe these final innings could lead to massive gains.   It's already happening… Stocks are up big over the last 18 months. But I don't believe we're at the top yet.   The reason is simple… Things don't look anything like they did at the top of the last Melt Up.   Let me explain…   During the last Melt Up, we saw the biggest gains in the tech-heavy Nasdaq Composite Index. It soared 200%-plus in 18 months as the Melt Up concluded. And prices hit truly ridiculous valuations along the way.   A lot of people point to today's valuations in the U.S. as a reason the recent gains can't continue. But here's the thing…

hot stocks to buy: America’s Car-Mart Inc.(CRMT)

Advisors’ Opinion:

  • [By Monica Gerson]

    America’s Car-Mart, Inc. (NASDAQ: CRMT) is projected to post its quarterly earnings at $0.58 per share on revenue of $149.13 million.

    Ryanair Holdings plc (ADR) (NASDAQ: RYAAY) is expected to report its quarterly earnings at $0.24 per share on revenue of $1.16 billion.

  • [By Monica Gerson]

    Analysts are expecting America’s Car-Mart, Inc. (NASDAQ: CRMT) to have earned $0.58 per share on revenue of $149.13 million in the latest quarter. America’s Car-Mart shares rose 2.06 percent to close at $23.25 on Friday.

hot stocks to buy: Mayne Pharma Group Limited (MAYNF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    We believe that two main risks currently exist. First, a few days ago, U.S. Department of Justice filed charges in generic drug price-fixing probe. The U.S. Department of Justice accused two former generic pharmaceutical executives of colluding with other generic manufacturers to fix prices – the first criminal charges stemming from a two-year investigation. Companies in the congressional probe have since publicly disclosed that they have received subpoenas, including Mylan NV (NASDAQ:MYL), Allergan (NYSE:AGN), which later sold its generics business to Teva (NASDAQ:TEVA), Lannett (NYSEMKT:LCI), Impax Laboratories (NASDAQ:IPXL), Endo International (NASDAQ

Leave a Reply

Your email address will not be published. Required fields are marked *